Gilead Sciences acquires German biotech company for $1.39 billion

The acquisition aims to boost Gilead ’s development and commercialization of therapeutics for treating the chronic hepatitis delta virus.

Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2020 Category: Biotechnology Authors: Dawn Kawamoto Source Type: news